Envoy Medical, Inc. · NASDAQ:COCH
Envoy Medical — Investor Presentation (August 2026)
30 slides from Envoy Medical's investor presentation, August 2026
Slide 1: Hear for Life – Investor Presentation August 2026
Hear for Life INVESTOR PRESENTATION August 2026 www.envoymedical.com NASDAQ: COCH
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as “estimate,” “plan,” “p
Slide 3: NASDAQ: COCH Market Data
NASDAQ: COCH Market Cap: $59.3MM* Shares Outstanding: 76.9MM* ADTV: 389K* *Market Data as of August 11, 2026
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS ✓ Hearing health company positioned to transform the multi-billion-dollar cochlear implant (CI) market with the first fully-implanted cochlear implant ✓ Acclaim® CI pivotal trial enrollment complete (March 11, 2026); all 56 patients successfully implanted and activated — first
Slide 5: Significant Market Opportunity: U.S. TAM ~$84B
. SIGNIFICANT MARKET OPPORTUNITY ❑ An estimated ~2.8M U.S. adults are candidates for cochlear implants1 ❑ Only about 5% of adults who could benefit from a CI have have gotten one 2 ❑ 95% of the adult CI market remains untapped. ❑ If approved, Acclaim® CI pricing is anticipated to be ~$30k, a premium
Slide 6: Large & Growing Need
LARGE & GROWING NEED • 14% of all Americans have clinically-relevant hearing loss with it becoming more common with age – nearly one-fourth of Americans over the age of sixty and two-thirds of Americans over the age of seventy. 1 • Hearing loss is the third most common chronic physical health condit
Slide 7: Levels of Hearing Loss: Envoy's Market Position
LEVELS OF HEARING LOSS Envoy’s Market Position Hearing Aids Esteem® Acclaim® CI Nasdaq: COCH 7
Slide 8: Traditional Cochlear Implants
TRADITIONAL COCHLEAR IMPLANTS Traditional cochlear implants require bulky external components to provide patient with perception of sound – without external wearable components the device does not work Magnets Sound processor (External) • Two magnets – one in the sound processor and one • Picks up s
Slide 9: External Components Have Drawbacks
EXTERNAL COMPONENTS HAVE DRAWBACKS • Visible Hardware: Noticeable and unsightly display of the wearer’s disability; stigma • Bedtime Removal: External devices are taken off at night leaving the user without hearing • Removal Before Showering/Activities: External devices can be damaged if exposed to
Slide 10: Fully Implanted Acclaim Cochlear Implant
FULLY IMPLANTED ACCLAIM® COCHLEAR IMPLANT • Developed to be the first of-its-kind fully implanted cochlear implant • Breakthrough Device Designation (FDA 2019) • Designed to address drawbacks of traditional cochlear implant and increase penetration rate • Acclaim ® CI Differentiation • Fully implant
Slide 11: First-of-its-Kind Fully Implanted Cochlear Implant
FIRST-OF-ITS-KIND FULLY IMPLANTED COCHLEAR IMPLANT DISCREET • No need for externally worn components • Designed to use the ear to pick up sound DEPENDABLE • Designed to allow 24/7 hearing • For use in many environments and activities EASE OF USE • No expensive external sound processors to replace wh
Slide 12: Acclaim CI Leverages Sensor from Envoy's First FDA-Approved Implant
ACCLAIM® CI LEVERAGES SENSOR FROM ENVOY’S FIRST FDA-APPOVED IMPLANT • Envoy’s Esteem® implant received FDA approval from the U.S. Food and Drug Administration in 2010. It was the first, and remains the only, fully implanted active hearing device to successfully receive FDA approval • Implanted in ~1
Slide 13: The Race to Fully Implanted CIs
THE RACE TO FULLY IMPLANTED CIs pa rt of Feasibility Study on Record • (USA) • (Australia) • (Europe) x Breakthrough Device Designation from U.S. FDA for Fully Implanted Cochlear Implant • x x x Investigational Device Exemption (IDE) application approved by FDA to begin Pivotal Clinical Trial in US.
Slide 14: Durable Differentiation
DURABLE DIFFERENTIATION Envoy Medical believes it has a superior design that will offer significant advantages over the competitive landscape • Cochlear and Med-El have both publicly stated that they are in early studies with their versions of “totally implantable” cochlear implants • Both designs a
Slide 15: Important Design Differences
IMPORTANT DESIGN DIFFERENCES Envoy Medical’s design is different from Cochlear and Med-El in important ways • Cochlear and Med-El use sub-cutaneous microphones. • Envoy Medical uses a piezoelectric middle ear sensor. • Cochlear and Med-El have microphones behind the ear. • Envoy Medical picks up sou
Slide 16: Concentrated & Mature Competitive Landscape
CONCENTRATED & MATURE COMPETITIVE LANDCAPE Market Share: ≈60% Market Share: ≈10% Market Share: ≈15% (ASX: COH) (SWX: SOON) $1.51B Revenue $4.49B Revenue Privately Held ~$4.69B Market Cap1 ~$15.5B Market Cap SOURCE: Cochlear Ltd. SOURCE: Advanced Bionics SOURCE: Med-EL COMPANIES DESCRIPTION Revenue (
Slide 17: Acclaim Cochlear Implant Pivotal Trial
ACCLAIM® COCHLEAR IMPLANT PIVOTAL TRIAL Pivotal Clinical Trial Evaluating Safety & Efficacy of the Fully Implanted Acclaim® Cochlear Implant (CI) ClinicalTrials.gov ID# NCT06699797 Trial Objective: Ability to safely and effectively treat severe to profound sensorineural hearing loss in adults Trial
Slide 18: Acclaim CI Pivotal Trial Sites
ACCLAIM® CI PIVOTAL TRIAL SITES • The 7 sites in the Pivotal trial are expected to serve as the backbone of the commercial launch • Mayo Clinic, Rochester, MN • Cleveland Clinic, Cleveland, OH • Community Hospital/Hearts for Hearing, Oklahoma City, OK • University of Florida, Gainesville, FL • Medic
Slide 19: Anticipated Timeline to Commercialization
ANTICIPATED TIMELINE TO COMMERCIALIZATION Q1 2027 Q4 2024 October 2025 Expect All Pivotal Q3 2022 FDA Granted Pivotal Clinical FDA Approves Trial Patients FDA Granted Trial IDE; Seven Expansion to Through 12-Mo. Early Feasibility Investigational Sites Second Phase of Follow-Up Visits Study IDE Selec
Slide 20: Target Sites for Implantation at Launch
TARGET SITES FOR IMPLANTATION AT LAUNCH 35 target launch sites include: • ACCLAIM CI® pivotal trial sites • Envoy’s Cochlear Implant Advisory Board (CIAB) Member sites • Current ESTEEM® implant sites • New sites that have indicated high interest in ACCLAIM CI® These 35 sites accounted for roughly 4,
Slide 21: Commercial Opportunity
COMMERCIAL OPPORTUNITY Reimbursement pathway for cochlear implants already exists • Exempt from Medicare’s “hearing aid exclusion” • Positive National Coverage Determination (NCD) 50.3 already exists for cochlear implants • Many private payors also cover cochlear implants for those who qualify • Cat
Slide 22: Executive Leadership Team
EXECUTIVE LEADERSHIP TEAM Brent T. Lucas, CEO Brent Lucas has been the Chief Executive Officer of Envoy Medical Corporation for the last ten years and brings over 18 years of experience with active implantable hearing devices. He is currently one of the longest serving CEOs of any cochlear implant m
Slide 23: Cochlear Implant Advisory Board
COCHLEAR IMPLANT ADVISORY BOARD Leading CI Experts Provide Support & Guidance as Envoy’s CI Advisory Board Surgeons Audiologists Dr. Colin L. Driscoll, M.D. ǀ Mayo Clinic (Rochester, MN) Jannine “Jan” Larky, M.A. ǀ Stanford Ear Institute (Palo Alto, CA) Dr. Elizabeth “Liz” Toh, M.D. ǀ Lahey Hospital
Slide 24: Recent Milestones & Corporate Priorities
RECENT MILESTONES & CORPORATE PRIORITIES • Acclaim®️ CI Pivotal Trial Enrollment • Enrollment complete — 56/56 patients implanted (March 11, 2026) • Implant activated for all 56 trial subjects – (April 22, 2026) • KOL presentation at the American Cochlear Implant Alliance Congress • Interim 6-month
Slide 25: Contact Details
Contact Details www.envoymedical.com/investors Investor Relations 651-361-8043 InvestorRelations@EnvoyMedical.com Phil Carlson For Media Inquiries: KCSA Strategic Communications Media@EnvoyMedical.com 212-896-1233 Envoy@kcsa.com
Slide 26: Appendix
APPENDIX
Slide 27: Envoy Medical, Inc. Board of Directors
ENVOY MEDICAL, INC. Board of Directors Chuck Brynelsen Brent Lucas Janis Smith-Gomez Michael Crowe Mona Patel Independent Director, Independent Director Susan Kantor Chas McKhann CEO of Envoy Independent Director, Independent Director, Board Chair Independent Director, Independent Director Medical N
Slide 28: Traditional Cochlear Implants Bypass Natural Ear Structures
TRADITIONAL COCHLEAR IMPLANTS BYPASS NATURAL EAR STRUCTURES 3 Sound waves are 1 transmitted Outer ear collects mechanically through sound waves and the ossicular chain to funnels them to the the cochlea ear canal 4 The cochlea converts sound waves to electrical signals which travel to the brain via
Slide 29: Envoy's Rechargeable Battery Expected to Last Several Days Between Charges
ENVOY’S RECHARGEABLE BATTERY EXPECTED TO LAST SEVERAL DAYS BETWEEN CHARGES Rechargeable Implanted Batteries Cochlear Implant Deep Brain Stimulation System Remain mobile while Envoy’s battery is charging with the similar to other charging system medical devices with implanted, Battery charging system
Slide 30: Hearing Loss: Global Market
HEARING LOSS: GLOBAL MARKET Key Facts from the World Health Organization1: • More than 1.5 billion people may have some form of hearing loss during their lifetime. • Approximately 430 million individuals have “disabling hearing loss” that requires intervention.2 • By 2050, these numbers are expected